EMEA-002007-PIP02-17

Key facts

Active substance
Cemiplimab
Therapeutic area
Oncology
Decision number
P/0385/2017
PIP number
EMEA-002007-PIP02-17
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
Route(s) of administration
Intravenous use
Contact for public enquiries
Regeneron Ireland U.C.
Tel. + 353 14112200
E-mail: EU-RegAffairs@regeneron.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating